{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:20:50Z","timestamp":1787160050672,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from\n                      <jats:italic>Poria cocos<\/jats:italic>\n                      , has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. This study aimed to elucidate the molecular impact and mechanisms of Pac in MASLD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Male C57BL\/6J mice were subjected to a high-fat diet (HFD) for 8 weeks, followed by a 4 weeks treatment with the Pac. Comprehensive assessments including physiological, biochemical, and histomorphological evaluations were performed post-treatment. Transcriptomic analysis of liver samples from normal control (NC), HFD, and HFD + high-dose Pac (Pac-H) groups was conducted, with validation through Western blot, and immunofluorescence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HFD induced biochemical abnormalities and liver injury, which were significantly reversed by Pac, as evidenced by decreased plasma levels of AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), TG (Triglyceride), and TC (Total cholesterol), and reduced hepatic TG and TC levels. Pac also mitigated lipid accumulation, peroxidation, and ferroptosis. Pac modulated the expression of PPAR\u03b1 (Peroxisome proliferator-activated receptor \u03b1), MAPKs (Mitogen-activated protein kinases), and ferroptosis pathways, thereby ameliorating MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study demonstrated that Pac inhibited the MAPKs signaling pathway and reduced hepatic ferroptosis, alleviated steatosis through PPAR\u03b1 regulation, offering a potential therapeutic strategy for MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1554850","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:40:16Z","timestamp":1746700816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPAR\u03b1"],"prefix":"10.3389","volume":"16","author":[{"given":"Guilin","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwensi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41419-023-05716-0","article-title":"The interaction between ferroptosis and inflammatory signaling pathways","volume":"21","author":"Chen","year":"2023","journal-title":"Cell Death Dis. Mar."},{"key":"B3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s11033-022-07965-2","article-title":"HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3\/MAPK pathway","volume":"50","author":"Ding","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.7150\/ijbs.85883","article-title":"Melatonin ameliorates hepatic ferroptosis in NAFLD by inhibiting ER stress via the MT2\/cAMP\/PKA\/IRE1 signaling pathway","volume":"19","author":"Guan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1096\/fj.201802724RR","article-title":"Iron accumulation causes impaired myogenesis correlated with MAPK signaling pathway inhibition by oxidative stress","volume":"33","author":"Ikeda","year":"2019","journal-title":"Faseb J. Aug"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1248\/bpb.b22-00440","article-title":"Pachymic acid inhibits growth and metastatic potential in liver cancer HepG2 and Huh7 cells","volume":"46","author":"Jiang","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jhep.2015.07.039","article-title":"CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt\/mTOR\/SREBP1c and P38\/PPAR\u03b1 pathways","volume":"63","author":"Li","year":"2015","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"154545","DOI":"10.1016\/j.phymed.2022.154545","article-title":"Xuanfei Baidu formula alleviates impaired mitochondrial dynamics and activated NLRP3 inflammasome by repressing NF-\u03baB and MAPK pathways in LPS-induced ALI and inflammation models","volume":"108","author":"Li","year":"2023","journal-title":"Phytomedicine"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108593","DOI":"10.1016\/j.pharmthera.2024.108593","article-title":"Berberine prevents NAFLD and HCC by modulating metabolic disorders","volume":"254","author":"Lin","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/cbin.12090","article-title":"Pachymic acid (PA) inhibits ferroptosis of cardiomyocytes via activation of the AMPK in mice with ischemia\/reperfusion-induced myocardial injury","volume":"48","author":"Liu","year":"2024","journal-title":"Cell Biol. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12935-015-0230-0","article-title":"Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells","volume":"15","author":"Ma","year":"2015","journal-title":"Cancer Cell Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1021\/acschemneuro.1c00516","article-title":"PPAR-\u0391 agonist GW7647 protects against oxidative stress and iron deposit via GPx4 in a transgenic mouse model of alzheimer's diseases","volume":"13","author":"Qu","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"109230","DOI":"10.1016\/j.cbi.2020.109230","article-title":"Taxifolin ameliorates iron overload-induced hepatocellular injury: modulating PI3K\/AKT and p38 MAPK signaling, inflammatory response, and hepatocellular regeneration","volume":"330","author":"Salama","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"B15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1101\/gad.334219.119","article-title":"MDM2 and MDMX promote ferroptosis by PPAR\u03b1-mediated lipid remodeling","volume":"34","author":"Venkatesh","year":"2020","journal-title":"Genes Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12964-023-01170-9","article-title":"The emerging roles of MAPK-AMPK in ferroptosis regulatory network","volume":"21","author":"Wang","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e52280","DOI":"10.15252\/embr.202052280","article-title":"PPAR\u03b1 alleviates iron overload-induced ferroptosis in mouse liver","volume":"3","author":"Xing","year":"2022","journal-title":"EMBO Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1007\/s00210-023-02492-8","article-title":"Urolithin C reveals anti-NAFLD potential via AMPK-ferroptosis axis and modulating gut microbiota","volume":"396","author":"Xu","year":"2023","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cmet.2020.10.011","article-title":"The metabolic underpinnings of ferroptosis","volume":"32","author":"Zheng","year":"2020","journal-title":"Cell Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1554850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T10:40:19Z","timestamp":1746700819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1554850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":20,"alternative-id":["10.3389\/fphar.2025.1554850"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1554850","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"1554850"}}